4.155USD-2.00%Mkt Cap: 1.52B USDP/E: —Last update: 2026-05-26
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious di…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.52B USD
Enterprise Value1.57B USD
Revenue (TTM)31.59M USD
Gross Profit4.86M USD
Net Income (TTM)-250.64M USD
Revenue/Share0.0960 USD
Last Price4.155 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees160
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74017N1054
Valuation
P/E (Trailing)—
P/E (Forward)-19.45
PEG—
EV/EBITDA-18.16
EV/Revenue49.62
P/S48.29
P/B72.54
EPS (TTM)-1.21
EPS (Forward)-0.22
52W Range
1.28069% of range5.470
52W High5.470 USD
52W Low1.280 USD
Profitability
Gross Margin50.20%
Oper. Margin-25.78%
EBITDA Margin-273.24%
Profit Margin-2588.21%
ROE-1198.61%
ROA-161.18%
Growth
Revenue Growth1633.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.83M USD
CapEx (TTM)2.00M USD
FCF Margin-285.21%
FCF Yield-5.93%
Net Debt42.00M USD
Net Debt/EBITDA-0.49
Balance Sheet
Debt/Equity4.70
Current Ratio4.82
Quick Ratio3.93
Book Value/Sh0.0590 USD
Cash/Share0.1580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)11.00 USD
Target Range11.00 USD – 11.00 USD
# Analysts2
Ownership
Shares Out.356.51M
Float189.75M
Insiders13.63%
Institutions71.00%
Short Interest
Short Ratio9.8d
Short % Float20.54%
Short % Out.11.16%
Shares Short39.77M
Short (prev mo.)39.66M
Technical
SMA 503.930 (+5.7%)
SMA 2003.921 (+6.0%)
Beta1.07
S&P 52W Chg28.31%
Avg Vol (30d)3.21M
Avg Vol (10d)3.87M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—